| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 36
| Issue : 1 | Page : 40-44 |
|
|
Prevalence and risk factors of erectile dysfunction among chronic hepatitis C male patients treated with pegylated interferon-α and ribavirin
Nagy Fawzy1, Hesham A Atia2, Sherif M Galal3, Jihan A Shawky3
1 Department of Psychiatry, Zagazig University, Zagazig, Egypt
2 Department of Internal Medicine, Zagazig University, Zagazig, Egypt
3 Department of Tropical Medicine, Zagazig University, Zagazig, Egypt
Correspondence Address:
Nagy Fawzy
Department of Psychiatry, Zagazig University, Zagazig, Sharkya
Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1110-1105.153776
|
|
|
Aim
The aim of the study was to determine the prevalence and risk factors of erectile dysfunction (ED) among chronic hepatitis C male patients treated with pegylated interferon-α and ribavirin.
Patients and methods
The sample consisted of 85 male patients treated with pegylated interferon-α2a and ribavirin for 12 months, recruited from Tropical and Internal Medicine outpatients of Zagazig University Hospitals. ED was prospectively studied by International Index of Erectile Function questionnaire, depression was assessed by Hospital Anxiety and Depression Scale, and routine laboratory investigations in addition to serum total and free testosterone were evaluated before, during, and 6 months after treatment.
Results
Prevalence of ED among chronic hepatitis C male patients was 40% (34 patients). There was significant deterioration of International Index of Erectile Function scores and Hospital Anxiety and Depression Scale with respect to basal values and a significant decrease in total and free testosterone with gradual improvement toward the end of treatment period. Emotional state and physical profiles were the most significant risk factors for sexual dysfunction.
Conclusion
ED is common among hepatitis C virus patients treated with pegylated interferon-α and ribavirin and it is multifactorial. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
